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Introduction: To the best of our knowledge, this is the first time triptorelin has been reported to cause benign
intracranial hypertension.
Case presentation: A 43-year-old Caucasian woman who suffered from chronic menorrhagia was started on
triptorelin, a gonadotrophin-releasing hormone analogue. Three days later, she developed gradually worsening
headaches accompanied by bilateral visual disturbance. Examination revealed bilateral papilledema and enlarged
blind spots on her visual fields. A diagnosis of benign intracranial hypertension was made and confirmed on
magnetic resonance imaging.
Conclusion: We recommend that patients at high risk (women who are overweight and of reproductive age) who
are using any gonadotrophin-releasing hormone analogue (for example, triptorelin) should be periodically
monitored for the possible development of benign intracranial hypertension.Introduction
A woman with menorrhagia was started on triptorelin, a
synthetic gonadotrophin-releasing hormone analogue,
mainly used in the treatment of prostate carcinoma and
endometriosis.
Three days later, she developed gradually worsening
headaches accompanied by bilateral visual disturbance.
An examination revealed bilateral papilledema and
enlarged blind spots on her visual fields. A diagnosis of
benign intracranial hypertension (BIH) was made and
confirmed on magnetic resonance imaging (MRI).Case presentation
A 43-year-old Caucasian woman was treated for chronic
menorrhagia with a MirenaW coil and traxenamic acid
with no success. Her gynecologist started her on triptor-
elin. Three days after the first dose, she attended our eye
centre casualty with progressively worsening headaches
accompanied by visual disturbances. She had no past
medical history of note, and was on no other medica-
tions at the time of presentation.* Correspondence: msxub@nottingham.ac.uk
1Department of Ophthalmology, Queen’s Medical Centre, Nottingham, NG7
2UH, UK
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reproduction in any medium, provided the orShe had unaided Snellen acuity of 6/36 improving to
6/18 with pinhole in either eye. Her color vision, pupils
and anterior segments were normal but she had bilateral
papilledema (Figure 1) and enlarged blind spots on her
visual fields (Figure 2). She was overweight (not obese)
with a body mass index of 28. She did not report any
recent-onset weight gain. The rest of her physical exam-
ination was unremarkable. MRI showed no intracranial
mass or ventricular dilatation but she had capacious
cerebral spinal fluid (CSF) spaces around her optic
nerves (Figure 3). A simultaneous magnetic resonance
venogram (MRV) displayed normal cerebral venous
sinuses.
She was urgently referred to our neurology team for a
lumbar puncture. Her CSF opening pressure was signifi-
cantly high at 43 cm but a CSF analysis was normal. A
diagnosis of BIH was made and she had further thera-
peutic CSF drainage done at the same time. She was
advised to discontinue triptorelin and start oral acetazo-
lamide 250 mg four times a day, although this was only
given for seven days and stopped, as our patient could
not tolerate it.
Within the next three days, her headaches ceased and her
visual acuity began improving gradually over the next three
weeks to 6/5 in both eyes. At the same time, the papille-
dema settled with near normal appearance of the discstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Fundal photographs showing bilateral papilledema.
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pressure on a lumbar puncture. Her visual fields showed re-
markable improvement with normalization of the blind
spots over the next three months.
Discussion
BIH, also known as pseudotumor cerebri, has an inci-
dence of 1.6 to 3.5 per 100,000 in women and is much
higher at 7.9 to 20 per 100,000 in women who are
overweight and of reproductive age [1]. Although by
definition the etiology of BIH is unknown, a plethora
of drugs and systemic conditions are associated with
this condition [2,3]. To explain the mechanism of BIH,
some hypotheses have been put forward. These include
the link between BIH and relatively obstructive seg-
ments in the distal transverse sinus, unrecognized
sinus thrombosis (undetected by MRI or MRV scans),Figure 2 Goldmann visual fields displaying bilateral enlarged blind spor the presence of increased arterial inflow with an ac-
companying low-grade stenosis of the transverse sinus
[2-5].
Administration of triptorelin initially stimulates the
anterior pituitary gland to release the gonadotrophins
luteinizing hormone and follicle-stimulating hormone.
However, its sustained use leads to their suppression.
To explain the BIH in this case, we speculate that
the Triptorelin-induced initial surge of gonadal ster-
oids may have caused non-occlusive thrombosis of the
dural venous sinuses by creating a venous hypertensive
state and impeding CSF drainage.
BIH usually develops several weeks to months after
the intake of the offending medication [6]. In our
case, the dramatic presentation and the very high CSF
opening pressure (43 cm) suggest a possible idiosyn-
cratic effect in our patient. Nevertheless, afterots.
Figure 3 Magnetic resonance imaging displaying capacious
cerebral spinal fluid spaces around the optic nerves.
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and the resolution of the papilledema were also very
dramatic. Such a causal relationship strongly suggests
triptorelin to be the cause of the BIH.
BIH has also been documented with the use of leu-
prorelin, which is similar in structure to triptorelin, and
this only strengthens the basis of our report [7]. In 1994,
Radhakrishnan et al. [8] reviewed the literature on BIH
associated with other diseases and with drugs. Within
their study, the authors insisted that the following
criteria should be met to include the disease or drug
within their list of causally related associations: at least
two cases should have been described; the reported cases
should have met all the criteria for the diagnosis of idio-
pathic intracranial hypertension; and intracranial duralFigure 4 Resolution of papilledema.sinus thrombosis should have been ruled out with rea-
sonable certainty.
Therefore gonadotrophin-releasing hormone analo-
gues fulfill the authors’ criteria as a causative agent for BIH
[8].
Conclusion
We recommend that patients at high risk (women who
are overweight and of reproductive age) who are using any
gonadotrophin-releasing hormone analogue (for example,
triptorelin) should be periodically monitored for the pos-
sible development of BIH.
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